DAVID THOMAS WENK M.D. NPI 1508087297

NPI Details

David Thomas Wenk, M.D. is a medical oncology internal medicine in Trinity, FL with 22 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. David Thomas Wenk, M.D. NPI is 1508087297. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

9320 STATE ROAD 54
TRINITY, FL
ZIP 34655-808
Phone: (727) 493-2513
Fax: (877) 917-2336

The NPI 1508087297 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Iron binding capacity (HCPCS:83550)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Magnesium level (HCPCS:83735)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Automated urinalysis test (HCPCS:81003)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Folic acid level, serum (HCPCS:82746)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Drawing of blood for a medical problem (HCPCS:99195)
• Red blood count, manual test (HCPCS:85044)
• Urinalysis, manual test (HCPCS:81002)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Red blood count, automated test (HCPCS:85045)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Erythropoietin (protein) level (HCPCS:82668)
• Transitional care management services for problem of high complexity (HCPCS:99496)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Hepatitis b core antibody measurement (HCPCS:86704)

The enumeration date for this NPI number is 5/1/2007 and was last updated on 9/2/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.